Pam Howland

Pam Howland, Vice President, Portfolio and Program Management, joined Bolt Biotherapeutics in 2022 with more than 20 years of experience driving biotechnology programs through Investigation New Drug (IND) and clinical development, and regulatory approval and commercial launch program phases. Ms. Howland previously worked at Lyell Immunopharma, where she was responsible for the advancement of the first two lead cell therapy programs through IND and into clinical trials. Prior to Lyell, Ms. Howland served as Vice President, Project and Alliance Management at Pellepharm Inc., a BridgeBio company, where in addition to program management responsibilities for the company’s three clinical trials, she also served as Alliance Manager for research collaboration supporting eventual commercialization of the program. Prior to Pellepharm, Ms. Howland spent ten years at Sunesis Pharmaceuticals (now Viracta Therapeutics), where she managed the vosaroxin program from Phase 2 development through planning and conduct of the Phase 3 clinical program, including regulatory submission and defense. Previous responsibilities included program management roles at Jazz Pharmaceuticals and Cepheid.